Viking Therapeutics, Inc. - Common Stock (VKTX)
36.47
+1.84 (5.31%)
NASDAQ · Last Trade: Nov 5th, 6:25 PM EST
Detailed Quote
| Previous Close | 34.63 |
|---|---|
| Open | 34.56 |
| Bid | 36.95 |
| Ask | 37.15 |
| Day's Range | 34.15 - 37.19 |
| 52 Week Range | 18.92 - 79.10 |
| Volume | 3,785,428 |
| Market Cap | 3.63B |
| PE Ratio (TTM) | -17.20 |
| EPS (TTM) | -2.1 |
| Dividend & Yield | N/A (N/A) |
| 1 Month Average Volume | 4,929,746 |
Chart
About Viking Therapeutics, Inc. - Common Stock (VKTX)
Viking Therapeutics is a biopharmaceutical company focused on the development of innovative therapies for metabolic and endocrine disorders. The company is engaged in advancing a portfolio of drug candidates aimed at addressing diseases with significant unmet medical needs, including non-alcoholic steatohepatitis (NASH) and obesity. Viking’s approach leverages proprietary drug development technologies to design and optimize novel therapeutic compounds, with an emphasis on safety and efficacy. Through its research and clinical trials, the company aims to bring transformative treatments to market that can improve patient outcomes and enhance quality of life. Read More
News & Press Releases
Stanley Druckenmiller's firm bought Viking Therapeutics stock (VKTX) during Q2 at $25.33. Now up 36%, VKTX shows a Golden Cross.
Via Benzinga · November 5, 2025
Zoom Communications is a good company, Cramer says. Still, he advises, "take a pass." Plus: Viking Therapeutics, Profrac and Altria.
Via Benzinga · November 5, 2025
Three factors took Viking's shares higher in the month.
Via The Motley Fool · November 5, 2025
It's a great idea to watch the latest moves of this expert investor.
Via The Motley Fool · November 4, 2025
Retail Investors Now Expect Viking Therapeutics To Bag A Deal After Novo Nordisk, Pfizer Engage In A Bidding War For Rival Metserastocktwits.com
Via Stocktwits · October 30, 2025
Biotech Viking Therapeutics has gained prominence over the past two years, but it could have plenty of upside left.
Via The Motley Fool · November 3, 2025
Viking's stock surged in one trading session after a positive clinical trial report last year.
Via The Motley Fool · November 2, 2025
These stocks may be down as of late, but investors shouldn't count them out in the long run.
Via The Motley Fool · October 31, 2025
Traders on Stocktwits linked Novo Nordisk’s renewed bid for Metsera to competition from Viking’s obesity drug VK2735, fueling further optimism.
Via Stocktwits · October 31, 2025
The company had positive updates on its clinical trials.
Via The Motley Fool · October 23, 2025
Viking Therapeutics shares are rising Thursday. The clinical-stage biopharmaceutical company reported third-quarter earnings and provided updates on clinical trials.
Via Benzinga · October 23, 2025
Morgan Stanley raised its price target on VKTX to $102 from $98 while maintaining an ‘Overweight’ rating.
Via Stocktwits · October 23, 2025
Viking Therapeutics stock popped Thursday on the lightening pace it's enrolling patients in a pair of obesity treatment tests.
Via Investor's Business Daily · October 23, 2025
Viking Therapeutics Q3 2025 results show an earnings miss, with shares falling. The company's key Phase 3 obesity trial remains on track.
Via Chartmill · October 22, 2025
Retail investors prepare for the first busy week in the Q3 earnings season, with Tesla, Netflix and Intel on deck.
Via Benzinga · October 20, 2025
These companies are jockeying for position in a potential $150 billion market opportunity.
Via The Motley Fool · October 20, 2025
These stocks have climbed in the triple digits over the past few years.
Via The Motley Fool · October 17, 2025
The smaller drugmaker is looking to disrupt a fast-growing market.
Via The Motley Fool · October 16, 2025
The company is readying to take on pharma giants Novo Nordisk and Eli Lilly.
Via The Motley Fool · October 13, 2025
As investors crowd into AI names at record highs, these three healthcare stocks offer more compelling valuations.
Via The Motley Fool · October 12, 2025
The small-cap pharmaceutical company may be the next in line as takeover fever heats up.
Via The Motley Fool · October 9, 2025